慈济化癌保生Ⅱ号方联合西医常规治疗原发性肺癌脾虚痰瘀证的临床效果分析  

Clinical effect analysis of treating primary lung cancer with a pattern of spleen deficiency and phlegm stasis by Ciji-Hua ai-BaoshengⅡformula combined with conventional western medicine

作　　者：郭雪卉 奚胜艳[1,2] 王彦晖 张春芳 米虽才 GUO Xuehui;XI Shengyan;WANG Yanhui;ZHANG Chunfang;MI Suicai(School of Medicine,Xiamen University,Xiamen 361102,China;Xiang an Hospital,Xiamen University,Xiamen 361102,China;Xiamen Hospital of Traditional Chinese Medicine,Xiamen 361015,China)

机构地区：[1]厦门大学医学院,福建厦门361102 [2]厦门大学附属翔安医院,福建厦门361102 [3]厦门市中医院,福建厦门361015

出　　处：《厦门大学学报（自然科学版）》2024年第5期954-963,共10页Journal of Xiamen University：Natural Science

基　　金：厦门市扶持中医药发展专项(XWZY-2023-0103);厦门市自然科学基金(3502Z20227171);福建省自然科学金(2018J01136)。

摘　　要：[目的]探讨慈济化癌保生Ⅱ号方联合西医常规治疗原发性肺癌患者脾虚痰瘀证的临床疗效.[方法]基于真实世界研究方法,收集整理2019年11月至2020年12月在厦门市中医院肿瘤科住院部和厦门燕来福国医馆门诊部诊治的65例原发性肺癌脾虚痰瘀证患者,分为仅接受单纯西医治疗方案的对照组和慈济化癌保生Ⅱ号方联合西医治疗的试验组.比较两组患者在治疗前后的卡氏评分、中医证候总积分、肿瘤标志物以及安全性指标(血常规和肝肾功能).[结果]治疗后两组患者的卡氏评分都较治疗前显著升高(P<0.05),但试验组治疗前后差值为5.45±7.11,对照组治疗前后差值为3.44±6.53,提示试验组改善效果明显优于对照组.两组中医证候总积分均显著降低(P<0.01),试验组治疗前后差值为4.48±2.82,对照组治疗前后差值为2.25±2.99,提示试验组的中医证候总积分改善效果明显优于对照组.试验组治疗前后各项单症评分均有显著差异(P<0.05),治疗效果明显;对照组治疗前后咳嗽、咯痰、气短、胸闷、胸痛单症评分有显著差异(P<0.05),但疲乏无力、食欲不振、心烦失眠单症评分差异无统计学意义(P>0.05).两组患者的肝肾功能、肿瘤标记物治疗前后差异均无统计学意义(P>0.05);但对照组治疗前后血小板和血红蛋白指标都显著降低(P<0.05),其骨髓抑制较试验组严重.[结论]慈济化癌保生Ⅱ号方联合西医治疗原发性肺癌脾虚痰瘀证可以改善患者临床症状,尤其明显改善患者的睡眠、饮食、体力等,提高了生存质量,减轻了单纯西医治疗带来的毒副反应,治疗效果佳且具有良好的安全性.[Objective]This study aims to investigate the clinical effect of Ciji-Hua ai-BaoshengⅡformula combined with conventional western medicine in the treatment of patients with primary lung cancer with a pattern of spleen deficiency and phlegm stasis.[Methods]Based on the real-world study(RWS)method,65 patients with primary lung cancer and a pattern of spleen deficiency and phlegm stasis,diagnosed and treated at the inpatient oncology department of Xiamen Hospital of Traditional Chinese Medicine and the outpatient department of Xiamen Yanlaifu National Medical Center from November 2019 to December 2020 were collected.Patients were classified into a control group that received only western medicine treatment(chemotherapy,radiotherapy,targeted therapy)and an experimental group that received western medicine treatment combined with Ciji-Hua ai-BaoshengⅡformula treatment.Karnofsky performance status(KPS)scores,traditional Chinese medicine(TCM)syndrome total scores,tumor-related markers[carcinoembryonic antigen(CEA),squamous cell carcinoma(SCC),neuron-specific enolase(NSE),and cytokeratin-21-fragment(Cyfra21-1)],toxic and side effects,safety indicators[blood routine(white blood cells,platelet counts,and hemoglobin concentration),and liver and kidney function(alanine aminotransferase,aspartate aminotransferase,urea,blood creatinine)]were compared between the two groups before and after treatment.SPSS 23.0 statistical software was used for the statistical analysis of the collected patient data.[Results]Before treatment,there was no statistical difference in baseline demographics,laboratory test results,or disease-related clinical symptoms between the two groups(P>0.05),indicating comparability between the two groups.After treatment,KPS scores in both groups were higher than before treatment(P<0.05),with the difference before and after treatment in the experimental group being 5.45±7.11,compared to 3.44±6.53 in the control group,indicating that the improvement in the experimental group was significantly better than that

关 键 词：慈济化癌保生Ⅱ号方 临床研究 中西医联合疗法 原发性肺癌 脾虚痰瘀证 

分 类 号：R735.7[医药卫生—肿瘤]